These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38329716)

  • 1. Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients.
    Meric-Bernstam F; Hollebecque A; Furuse J; Oh DY; Bridgewater JA; Shimura M; Anderson B; Hangai N; Wacheck V; Goyal L
    Clin Cancer Res; 2024 Apr; 30(8):1466-1477. PubMed ID: 38329716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring
    Meric-Bernstam F; Bahleda R; Hierro C; Sanson M; Bridgewater J; Arkenau HT; Tran B; Kelley RK; Park JO; Javle M; He Y; Benhadji KA; Goyal L
    Cancer Discov; 2022 Feb; 12(2):402-415. PubMed ID: 34551969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Futibatinib for
    Goyal L; Meric-Bernstam F; Hollebecque A; Valle JW; Morizane C; Karasic TB; Abrams TA; Furuse J; Kelley RK; Cassier PA; Klümpen HJ; Chang HM; Chen LT; Tabernero J; Oh DY; Mahipal A; Moehler M; Mitchell EP; Komatsu Y; Masuda K; Ahn D; Epstein RS; Halim AB; Fu Y; Salimi T; Wacheck V; He Y; Liu M; Benhadji KA; Bridgewater JA;
    N Engl J Med; 2023 Jan; 388(3):228-239. PubMed ID: 36652354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
    Javle M; King G; Spencer K; Borad MJ
    Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.
    Gandhy SU; Casak SJ; Mushti SL; Cheng J; Subramaniam S; Zhao H; Zhao M; Bi Y; Liu G; Fan J; Adeniyi O; Charlab R; Kufrin D; Thompson MD; Jarrell K; Auth D; Lemery SJ; Pazdur R; Kluetz PG; Fashoyin-Aje LA
    Clin Cancer Res; 2023 Oct; 29(20):4027-4031. PubMed ID: 37289037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma.
    Hoy SM
    Target Oncol; 2024 May; 19(3):473-480. PubMed ID: 38724820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
    Bahleda R; Meric-Bernstam F; Goyal L; Tran B; He Y; Yamamiya I; Benhadji KA; Matos I; Arkenau HT
    Ann Oncol; 2020 Oct; 31(10):1405-1412. PubMed ID: 32622884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer.
    De SK
    Curr Med Chem; 2024; 31(6):666-670. PubMed ID: 37062061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
    Frampton JE
    Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
    Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
    J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
    Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
    Doi T; Shitara K; Kojima T; Kuboki Y; Matsubara N; Bando H; Yoh K; Naito Y; Hirai H; Kurokawa Y; Kato T; Morizane C
    Cancer Sci; 2023 Feb; 114(2):574-585. PubMed ID: 35838190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.
    Lacouture ME; Sibaud V; Anadkat MJ; Kaffenberger B; Leventhal J; Guindon K; Abou-Alfa G
    Oncologist; 2021 Feb; 26(2):e316-e326. PubMed ID: 33021006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
    Patel TH; Marcus L; Horiba MN; Donoghue M; Chatterjee S; Mishra-Kalyani PS; Schuck RN; Li Y; Zhang X; Fourie Zirkelbach J; Charlab R; Liu J; Yang Y; Lemery SJ; Pazdur R; Theoret MR; Fashoyin-Aje LA
    Clin Cancer Res; 2023 Mar; 29(5):838-842. PubMed ID: 36206041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Futibatinib for cholangiocarcinomas with a FGFR2 fusion or rearrangement, locally advanced or metastatic].
    Noé C; Edeline J
    Bull Cancer; 2023 Oct; 110(10):985-986. PubMed ID: 37500387
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacological characteristics and clinical effectiveness of Futibatinib (Lytgobi
    Takagaki K; Okude R; Hirayama N; Sootome H; Hirai H
    Nihon Yakurigaku Zasshi; 2024 Nov; 159(6):423-432. PubMed ID: 39384389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Futibatinib: First Approval.
    Syed YY
    Drugs; 2022 Dec; 82(18):1737-1743. PubMed ID: 36441501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
    Javle M; Roychowdhury S; Kelley RK; Sadeghi S; Macarulla T; Weiss KH; Waldschmidt DT; Goyal L; Borbath I; El-Khoueiry A; Borad MJ; Yong WP; Philip PA; Bitzer M; Tanasanvimon S; Li A; Pande A; Soifer HS; Shepherd SP; Moran S; Zhu AX; Bekaii-Saab TS; Abou-Alfa GK
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):803-815. PubMed ID: 34358484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.